Cover Image
市場調查報告書

後天性罕見血液疾病治療藥的全球市場:2015-2019年

Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 325813
出版日期 內容資訊 英文 114 Pages
訂單完成後即時交付
價格
Back to Top
後天性罕見血液疾病治療藥的全球市場:2015-2019年 Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
出版日期: 2015年03月11日 內容資訊: 英文 114 Pages
簡介

後天性罕見血液疾病治療藥的全球市場預計從2014年到2019年以12.29%的年複合成長率發展。

本報告提供全球後天性罕見血液疾病的治療藥的市場相關調查、後天性罕見血液疾病的主要類型和概要、主要產品簡介、開發平台趨勢、新的治療選項、各疾病區分、地區的市場規模的變化與預測、市場成長的各種影響因素分析、競爭情形與市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Soliris
  • Nplate
  • Revlimid
  • Vidaza
  • Promacta
  • Jakafi
  • Rituxan

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 市場概要

  • 特發性血小板減少紫斑症 (ITP:Idiopathic Thrombocytopenic Purpura)
    • 關於疾病
    • 流行病學
    • 病因
    • 病理生理學
    • 疾病治療
  • 骨髓發育不良症候群 (MDS:Myelodysplastic Syndromes)
    • 關於疾病
    • 流行病學
    • 病因
    • 病理生理學
    • 疾病治療
  • 骨髓纖維化 (MF:Myelofibrosis)
    • 關於疾病
    • 流行病學
    • 病因
    • 病理生理學
    • 疾病治療
  • 發作性夜間血尿症 (PNH:Paroxysmal Nocturnal Hemoglobinuria)
    • 關於疾病
    • 流行病學
    • 病因
    • 病理生理學
    • 疾病治療
  • 真性多血症 (PV:Polycythemia Vera)
    • 關於疾病
    • 流行病學
    • 病因
    • 病理生理學
    • 疾病治療
  • 開發平台分析
  • 新的治療選擇

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 各適應症市場

ITP:市場規模、預測 MDS:市場規模、預測 MF:市場規模、預測 PNH:市場規模、預測 PV:市場規模、預測

第10章 各地區市場

第11章 購買標準

第12章 推動市場成長要素

第13章 成長推動因素與其影響

第14章 市場課題

第15章 成長推動因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • 主要藥物的競爭評估
    • Alexion Pharmaceuticals
    • Amgen
    • Celgene
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Incyte
  • 其他有潛力的供應商

第19章 主要供應商分析

  • F. Hoffmann-La Roche Ltd.
  • Celgene
  • Alexion
  • Amgen
  • Incyte
  • GlaxoSmithKline
    • 主要資料
    • 產業概要
    • 各產業分類收益
    • 各地區收益
    • 近幾年的發展趨勢
    • SWOT分析等

第20章 相關報告

圖表清單

目錄
Product Code: IRTNTR5409

About Acquired Orphan Blood Diseases Therapeutics

Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. The acquired orphan blood diseases are developed in the blood after the post fetal life; they are not caused because of genetic reasons. The major orphan blood diseases that contribute to acquired orphan blood diseases are the following: ITP, MDS, MF PNH, and PV.

TechNavio's analysts forecast the Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS.

TechNavio's report, the Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Acquired Orphan Blood Diseases Therapeutics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Alexion Pharmaceuticals
  • Amgen
  • Celgene
  • F. Hoffmann- La Roche
  • GlaxoSmithKline
  • Incyte

Other Prominent Vendors

  • Cyclacel Pharmaceuticals
  • CTI Biopharma (Cell Therapeutics)
  • Eli Lilly
  • Gilead Sciences
  • Onconova Therapeutics
  • MebVax Therapeutics
  • Novartis
  • Sanofi
  • Shire Pharmaceuticals
  • S* Bio Pte

Market Driver

  • Exemption from Pricing Obstacle
  • For a full, detailed list, view our report

Market Challenge

  • Companies Hesitant to Invest in Rare Diseases Therapeutics
  • For a full, detailed list, view our report

Market Trend

  • Benefit from Untapped Market
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1. Soliris
  • 04.2. Nplate
  • 04.3. Revlimid
  • 04.4. Vidaza
  • 04.5. Promacta
  • 04.6. Jakafi
  • 04.7. Rituxan

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Diseases Overview

  • 07.1. ITP
    • 07.1.1. Understanding the Disease
    • 07.1.2. Epidemiology
    • 07.1.3. Etiology
    • 07.1.4. Pathophysiology
    • 07.1.5. Management of Disease
  • 07.2. MDS
    • 07.2.1. Understanding the Disease
    • 07.2.2. Epidemiology
    • 07.2.3. Etiology
    • 07.2.4. Pathophysiology
    • 07.2.5. Management of Disease
  • 07.3. MF
    • 07.3.1. Understanding the Disease
    • 07.3.2. Epidemiology
    • 07.3.3. Etiology
    • 07.3.4. Pathophysiology
    • 07.3.5. Management of Disease
  • 07.4. PNH
    • 07.4.1. Understanding the Disease
    • 07.4.2. Epidemiology
    • 07.4.3. Etiology
    • 07.4.4. Pathophysiology
    • 07.4.5. Management of Disease
  • 07.5. PV
    • 07.5.1. Understanding the Disease
    • 07.5.2. Epidemiology
    • 07.5.3. Etiology
    • 07.5.4. Pathophysiology
    • 07.5.5. Management of Disease
  • 07.6. Pipeline Analysis
  • 07.7. Emerging Treatment Options

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Indication Type

    • 09.1.1. Market Size and Forecast for ITP
    • 09.1.2. Market Size and Forecast for MDS
    • 09.1.3. Market Size and Forecast for MF
    • 09.1.4. Market Size and Forecast for PNH
    • 09.1.5. Market Size and Forecast for PV

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. Competitive Assessment of Top Drugs
    • 18.2.2. Alexion Pharmaceuticals
    • 18.2.3. Amgen
    • 18.2.4. Celgene
    • 18.2.5. F. Hoffmann-La Roche
    • 18.2.6. GlaxoSmithKline
    • 18.2.7. Incyte

Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. F. Hoffmann-La Roche Ltd.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation
    • 19.1.4. Business Segmentation by Revenue 2012 and 2013
    • 19.1.5. Sales by Geography
    • 19.1.6. Business Strategy
    • 19.1.7. Key Information
    • 19.1.8. SWOT Analysis
  • 19.2. Celgene
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Strategy
    • 19.2.4. Business Segmentation by Revenue
    • 19.2.5. Sales by Geography
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Alexion
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Geographical Segmentation by Revenue 2013
    • 19.3.4. Business Strategy
    • 19.3.5. Recent Developments
    • 19.3.6. SWOT Analysis
  • 19.4. Amgen
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Product Portfolio by Revenue 2013
    • 19.4.5. Business Segmentation by Revenue 2012 and 2013
    • 19.4.6. Geographical Segmentation by Revenue 2013
    • 19.4.7. Business Strategy
    • 19.4.8. Recent Developments
    • 19.4.9. SWOT Analysis
  • 19.5. Incyte
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Revenue Segmentation by 2013
    • 19.5.4. Revenue Segmentation by 2012 and 2013
    • 19.5.5. Geographical Segmentation
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis
  • 19.6. GlaxoSmithKline
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Business Segmentation
    • 19.6.4. Business Segmentation by Revenue 2012 and 2013
    • 19.6.5. Sales by Geography
    • 19.6.6. Pipeline Products
    • 19.6.7. Business Strategy
    • 19.6.8. Key Information
    • 19.6.9. SWOT Analysis
    • 19.6.10. Strengths
    • 19.6.11. Weaknesses
    • 19.6.12. Opportunities
    • 19.6.13. Threats

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of ITP
  • Exhibit 3: Snapshot of MDS
  • Exhibit 4: Snapshot of MF
  • Exhibit 5: Snapshot of PNH
  • Exhibit 6: Snapshot of PV
  • Exhibit 7: Global Acquired Orphan Blood Diseases Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 8: Global Acquired Orphan Blood Diseases Therapeutics Market Segmentation by Indication Type
  • Exhibit 9: Global Acquired Orphan Blood Diseases Therapeutics Market Revenue Comparison by Indication, 2014 and 2019 (US$ million)
  • Exhibit 10: Global Acquired Orphan Blood Diseases Therapeutics Market Percent Share by Indication, 2014 and 2019
  • Exhibit 11: Market Size and Forecast for ITP Market 2014-2019 (US$ million)
  • Exhibit 12: Market Size and Forecast for MDS Market 2014-2019 (US$ million)
  • Exhibit 13: Market Size and Forecast for MF Market 2014-2019 (US$ million)
  • Exhibit 14: Market Size and Forecast for PNH Market 2014-2019 (US$ million)
  • Exhibit 15: Market Size and Forecast for PV Market 2014-2019 (US$ million)
  • Exhibit 16: Geographical Segmentation of Global Acquired Orphan Blood Diseases Therapeutics Market in 2014
  • Exhibit 17: Marketing Exclusivity for Orphan Drugs in Some Regions
  • Exhibit 18: Revenue Comparison of Top Drugs for Acquired Orphan Blood Diseases Therapeutics market in 2013 (US$ million)
  • Exhibit 19: Revenue Comparison and YoY Growth for Soliris from 2012-2014 (US$ million)
  • Exhibit 20: Global Market Forecast for Soliris from 2014-2019 (US$ million)
  • Exhibit 21: Revenue Comparison and YoY Growth for Nplate from 2011-2013 (US$ million)
  • Exhibit 22: Revenue Comparison and YoY Growth for Revlimid from 2011-2013 (US$ million)
  • Exhibit 23: Revenue Comparison and YoY Growth for Vidaza from 2011-2013 (US$ million)
  • Exhibit 24: Revenue Comparison for Rituxan from 2012-2013 (US$ million)
  • Exhibit 25: Revenue Comparison and YoY Growth for Promacta 2011-2014 (US$ million)
  • Exhibit 26: Revenue Comparison for Jakafi from 2012-2013 (US$ million)
  • Exhibit 27: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 28: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 29: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 30: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 31: Celgene: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 32: Celgene: Sales by Geography 2013
  • Exhibit 33: Alexion: Geographical Segmentation by Revenue 2013
  • Exhibit 34: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 35: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 36: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 37: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 38: Incyte Corporation: Revenue Segmentation by 2013 (US$ million)
  • Exhibit 39: Incyte Corporation: Revenue Segmentation by 2012 and 2013 (US$ million)
  • Exhibit 40: Incyte Corporation: Geographical Segmentation
  • Exhibit 41: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 42: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 43: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 44: GlaxoSmithKline: Pipeline Products 2013
Back to Top